Oisin Biotechnologies is a drug development company focused on mitigating the senolytic technology to combat age-related diseases.
Oisin Biotechnologies has raised $10.0M in total funding. The most recent round was Series A. The last funding was announced in August 2025.
Oisin Biotechnologies's investors include AbbVie, Avant Global LLC, Healthspan Capital, Hedgewood, Kingsley Advani.
Oisin Biotechnologies is headquartered in Seattle, United States.
Oisin Biotechnologies is a drug development company focused on mitigating the senolytic technology to combat age-related diseases.
Oisin Biotechnologies is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oisin Biotechnologies — Funding & Investors." VCBacked, August 1, 2025, https://www.vcbacked.co/company/oisin-biotechnologies. Accessed October 1, 2026.
VCBacked. (2025). Oisin Biotechnologies — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/oisin-biotechnologies
{{cite web |title=Oisin Biotechnologies — Funding & Investors |url=https://www.vcbacked.co/company/oisin-biotechnologies |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated